Nektar Therapeutics

NKTR Healthcare Biotechnology

Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.

35.78 1.94 −5.14%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
3/9
Altman Z
−17.07
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
389.10 296.13 1,335.35 1,324.86 1,061.90 733.96 504.98 303.62 255.23 245.75
Receivables
15.68 5.01 43.21 36.80 38.89 22.49 5.98 1.21 — —
Inventory
11.11 10.73 11.38 12.67 15.29 15.80 19.20 16.10 — —
Other current assets
10.06 14.95 47.74 47.22 21.93 23.33 15.81 9.78 6.07 20.51
Total current assets
425.95 326.82 1,437.69 1,421.55 1,138.01 795.58 545.97 330.70 261.29 266.27
Property, Plant, Equpment (Net)
65.60 47.46 48.85 65.67 59.66 60.51 32.45 18.86 3.41 2.06
Long-Term Investments
— 57.09 582.89 279.12 136.66 64.83 — 25.83 26.09 3.49
Goodwill and Intangible Assets (Total)
76.50 76.50 76.50 76.50 76.50 76.50 76.50 — — —
Long-term assets (Other)
0.82 0.99 4.24 0.34 1.46 2.74 2.25 4.64 4.65 5.65
Total non-current assets
142.92 182.05 712.49 555.81 400.76 321.61 164.63 67.33 42.56 14.14
Total Assets
568.87 508.87 2,150.17 1,977.36 1,538.77 1,117.19 710.60 398.03 303.85 280.41
Accounts Payable
2.82 4.78 5.85 19.23 22.14 9.75 12.98 9.85 11.56 10.77
Accrued Expenses
30.44 25.77 52.68 51.40 58.74 42.54 36.56 22.16 29.97 22.27
Current Part of Debt
3.00 — — 252.89 — — — — — —
Current Revenue (Deferred)
14.35 18.95 13.89 5.52 0.09 — — — — —
Other current liabilities
19.91 0.45 0.49 — — — — — — —
Total current liabilities
72.22 56.16 82.00 353.89 115.78 85.20 68.20 51.27 61.40 53.54
Long Term Debt (Total)
243.46 245.21 246.95 — — — — — — —
Non-current Revenue (Deferred)
51.89 19.02 10.74 2.55 — — — — — —
Non-current Liabilities (Other)
113.17 100.65 92.90 72.79 209.32 226.75 162.93 117.26 99.02 71.78
Total non-current liabilities
408.52 364.88 350.60 218.07 345.69 352.48 275.76 215.78 181.71 137.04
Total liabilities
480.75 421.04 432.60 571.97 461.47 437.68 343.96 267.05 243.11 190.57
Additional Paid In Capital
2,111.48 2,207.87 3,147.93 3,271.10 3,388.73 3,516.64 3,574.72 3,608.14 3,659.89 3,850.10
Common Stock (Net)
0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.00 0.00
Retained Earnings
(2,021.01) (2,117.94) (1,424.05) (1,864.72) (2,309.16) (2,832.99) (3,201.19) (3,477.25) (3,596.21) (3,760.29)
Treasury Stock
— — — — — — — — 3.00 —
Common Equity (Total)
88.12 87.83 1,717.58 1,405.39 1,077.30 679.51 366.64 130.99 60.74 89.83
Shareholders Equity (Total)
88.13 87.83 1,717.58 1,405.39 1,077.30 679.51 366.64 130.99 60.74 89.83
Shareholders Equity and Liabilities (Total)
568.87 508.87 2,150.17 1,977.36 1,538.77 1,117.19 710.60 398.03 303.85 280.41
Shares (Common)
10.22 10.64 11.57 11.77 12.01 12.37 12.58 12.77 12.39 20.38
Shareholders Equity (Tangible)
11.62 11.33 1,641.07 1,328.89 1,000.79 603.01 290.14 130.99 60.74 89.83
Net Debt
(142.64) (50.92) (1,088.40) (1,071.97) (1,061.90) (733.95) (504.98) (303.62) (255.23) (245.75)
Total Debt
246.46 245.21 246.95 252.89 320.00 291.00 258.00 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates